Related Experiment Videos

Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized

Colin Baigent1, Martin J Landray, David C Wheeler

  • 1Clinical Trial Service Unit & Epidemiological Studies Unit, Oxford, UK. colin.baigent@ctsu.ox.ac.uk

Seminars in Dialysis
|November 10, 2007
PubMed

Insights

Higher cholesterol levels do not increase mortality risk in dialysis patients, unlike in the general population. Studies show a negative association at low cholesterol and a flat or weak positive association at high cholesterol levels.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Epidemiology

Background:

  • Elevated cholesterol is a known risk factor for coronary heart disease (CHD) in the general population.
  • The association between cholesterol and mortality in dialysis patients is unexpectedly unclear.
  • Dialysis patients face a high burden of cardiovascular disease and mortality.

Purpose of the Study:

  • To review prospective studies examining the relationship between total cholesterol and mortality in dialysis patients.
  • To understand the paradoxical association between cholesterol and mortality in this specific population.
  • To identify factors that may explain the lack of a clear positive association.

Main Methods:

  • Systematic review of prospective cohort studies.
  • Analysis of the association between total cholesterol levels and all-cause mortality.
  • Examination of associations stratified by cholesterol levels (below average, above average).

Main Results:

  • A negative association between total cholesterol and mortality was observed at below-average cholesterol levels.
  • A flat or weakly positive association was found at above-average cholesterol levels.
  • The lack of a strong positive association may be due to a high proportion of non-CHD vascular deaths.

Conclusions:

  • The cholesterol-mortality paradox in dialysis patients may be influenced by reverse causality and confounding factors.
  • Randomized controlled trials are necessary to definitively assess cholesterol's role in vascular disease risk for dialysis patients.
  • Ongoing trials of cholesterol-lowering therapies are expected to provide crucial insights.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...